Bessemer Group Inc. Reduces Position in Integra LifeSciences Holdings Corporation (IART)

Bessemer Group Inc. lessened its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 4.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,100 shares of the life sciences company’s stock after selling 2,700 shares during the period. Bessemer Group Inc. owned 0.07% of Integra LifeSciences Holdings Corporation worth $2,680,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. LS Investment Advisors LLC grew its stake in shares of Integra LifeSciences Holdings Corporation by 4.6% in the 2nd quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after buying an additional 111 shares during the period. Pinebridge Investments L.P. grew its stake in shares of Integra LifeSciences Holdings Corporation by 2.2% in the 2nd quarter. Pinebridge Investments L.P. now owns 7,971 shares of the life sciences company’s stock valued at $435,000 after buying an additional 174 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Integra LifeSciences Holdings Corporation by 3.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock valued at $295,000 after buying an additional 187 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Integra LifeSciences Holdings Corporation by 8.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after buying an additional 218 shares during the period. Finally, Louisiana State Employees Retirement System grew its stake in shares of Integra LifeSciences Holdings Corporation by 1.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 24,600 shares of the life sciences company’s stock valued at $1,341,000 after buying an additional 300 shares during the period. 83.99% of the stock is owned by institutional investors.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) traded down $0.19 during trading on Wednesday, reaching $47.56. 39,360 shares of the company’s stock traded hands, compared to its average volume of 606,873. The stock has a market cap of $3,719.83, a P/E ratio of 26.19, a P/E/G ratio of 2.06 and a beta of 0.64. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The company had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. During the same quarter last year, the business earned $0.93 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 1.87 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/11/22/bessemer-group-inc-has-2-68-million-holdings-in-integra-lifesciences-holdings-corporation-iart.html.

In other Integra LifeSciences Holdings Corporation news, Director Barbara B. Hill bought 10,768 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, with a total value of $502,434.88. Following the completion of the acquisition, the director now owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the transaction, the vice president now owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The disclosure for this sale can be found here. 21.50% of the stock is owned by insiders.

Several analysts have recently weighed in on IART shares. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “buy” rating and set a $57.00 price target for the company in a research note on Tuesday, October 3rd. Barclays PLC reaffirmed an “equal weight” rating and set a $53.00 price objective (up previously from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. TheStreet cut shares of Integra LifeSciences Holdings Corporation from a “b” rating to a “c+” rating in a research report on Thursday, October 26th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation in a report on Monday, September 18th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $53.82.

Integra LifeSciences Holdings Corporation Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply